Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania

Trial Profile

Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Ferric carboxymaltose (Primary) ; Ferrous sulfate; Folic acid
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Apr 2017 Planned End Date changed from 1 Jan 2017 to 1 Apr 2018.
    • 22 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top